Cargando…
Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report
BACKGROUND: Rhabdomyolysis is a potentially life-threatening disease caused by melting or necrosis of skeletal muscle cells and leakage of muscle components into the bloodstream. It has been reported that the interaction of the HMG-CoA reductase inhibitor rosuvastatin with the renal anemia drug vada...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084597/ https://www.ncbi.nlm.nih.gov/pubmed/37032382 http://dx.doi.org/10.1186/s40780-023-00281-2 |
_version_ | 1785021771273994240 |
---|---|
author | Sakurama, Keiki Iguchi, Yuki Haruki, Sara Hata, Yusuke Hiraga, Madoka Yumoto, Shinya Kai, Yutaka |
author_facet | Sakurama, Keiki Iguchi, Yuki Haruki, Sara Hata, Yusuke Hiraga, Madoka Yumoto, Shinya Kai, Yutaka |
author_sort | Sakurama, Keiki |
collection | PubMed |
description | BACKGROUND: Rhabdomyolysis is a potentially life-threatening disease caused by melting or necrosis of skeletal muscle cells and leakage of muscle components into the bloodstream. It has been reported that the interaction of the HMG-CoA reductase inhibitor rosuvastatin with the renal anemia drug vadadustat increases the blood concentration of rosuvastatin in vitro. In this study, we report a case of suspected rhabdomyolysis caused by the drug interaction of rosuvastatin and vadadustat in clinical practice. CASE PRESENTATION: A 62-year-old male with medical records of hypertension, myocardial infarction, chronic renal failure, renal anemia, dyslipidemia, and alcoholic liver disease. The patient had been diagnosed with chronic kidney disease (CKD) at the Department of Nephrology, and treated by outpatient care with renal support therapy for the past two years. On X-63 day, his prescription was rosuvastatin (10 mg/day) and a continuous erythrocyte-stimulating agent, epoetin beta pegol (genetical recombination, 100 μg). X-Day 0, blood tests revealed creatine phosphokinase (CPK) 298 U/L, serum creatinine (SCr) 5.26 mg/dL, and hemoglobin (Hb) 9.5 g/dL; thus, the prescription was changed from epoetin beta pegol 100 μg to vadadustat 300 mg/day. On X + day 80, a prescription for a diuretic (azosemide 15 mg/day) was added for swelling of the lower extremities. On X + day 105, we found CPK 16,509 U/L, SCr 6.51 mg/dL, and Hb 9.5 g/dL. The patient was diagnosed as rhabdomyolysis and hospitalized. After hospitalization, rosuvastatin and vadadustat were discontinued and we administered intravenous fluids. Thereafter, CPK and SCr values of the patient improved. On X + day 122, CPK improved to 29 U/L, SCr to 2.6 mg/dL, and Hb to 9.6 g/dL, and he was discharged on X + day 124. At discharge, rosuvastatin 2.5 mg/day was resumed. A blood test on X + day 133 showed CPK 144 U/L and SCr 4.2 mg/dL. CONCLUSION: We experienced a case of rhabdomyolysis caused by drug interactions between rosuvastatin and vadadustat. |
format | Online Article Text |
id | pubmed-10084597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100845972023-04-11 Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report Sakurama, Keiki Iguchi, Yuki Haruki, Sara Hata, Yusuke Hiraga, Madoka Yumoto, Shinya Kai, Yutaka J Pharm Health Care Sci Case Report BACKGROUND: Rhabdomyolysis is a potentially life-threatening disease caused by melting or necrosis of skeletal muscle cells and leakage of muscle components into the bloodstream. It has been reported that the interaction of the HMG-CoA reductase inhibitor rosuvastatin with the renal anemia drug vadadustat increases the blood concentration of rosuvastatin in vitro. In this study, we report a case of suspected rhabdomyolysis caused by the drug interaction of rosuvastatin and vadadustat in clinical practice. CASE PRESENTATION: A 62-year-old male with medical records of hypertension, myocardial infarction, chronic renal failure, renal anemia, dyslipidemia, and alcoholic liver disease. The patient had been diagnosed with chronic kidney disease (CKD) at the Department of Nephrology, and treated by outpatient care with renal support therapy for the past two years. On X-63 day, his prescription was rosuvastatin (10 mg/day) and a continuous erythrocyte-stimulating agent, epoetin beta pegol (genetical recombination, 100 μg). X-Day 0, blood tests revealed creatine phosphokinase (CPK) 298 U/L, serum creatinine (SCr) 5.26 mg/dL, and hemoglobin (Hb) 9.5 g/dL; thus, the prescription was changed from epoetin beta pegol 100 μg to vadadustat 300 mg/day. On X + day 80, a prescription for a diuretic (azosemide 15 mg/day) was added for swelling of the lower extremities. On X + day 105, we found CPK 16,509 U/L, SCr 6.51 mg/dL, and Hb 9.5 g/dL. The patient was diagnosed as rhabdomyolysis and hospitalized. After hospitalization, rosuvastatin and vadadustat were discontinued and we administered intravenous fluids. Thereafter, CPK and SCr values of the patient improved. On X + day 122, CPK improved to 29 U/L, SCr to 2.6 mg/dL, and Hb to 9.6 g/dL, and he was discharged on X + day 124. At discharge, rosuvastatin 2.5 mg/day was resumed. A blood test on X + day 133 showed CPK 144 U/L and SCr 4.2 mg/dL. CONCLUSION: We experienced a case of rhabdomyolysis caused by drug interactions between rosuvastatin and vadadustat. BioMed Central 2023-04-10 /pmc/articles/PMC10084597/ /pubmed/37032382 http://dx.doi.org/10.1186/s40780-023-00281-2 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Sakurama, Keiki Iguchi, Yuki Haruki, Sara Hata, Yusuke Hiraga, Madoka Yumoto, Shinya Kai, Yutaka Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report |
title | Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report |
title_full | Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report |
title_fullStr | Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report |
title_full_unstemmed | Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report |
title_short | Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report |
title_sort | rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084597/ https://www.ncbi.nlm.nih.gov/pubmed/37032382 http://dx.doi.org/10.1186/s40780-023-00281-2 |
work_keys_str_mv | AT sakuramakeiki rhabdomyolysiscausedbyinteractionbetweenrosuvastatinandvadadustatacasereport AT iguchiyuki rhabdomyolysiscausedbyinteractionbetweenrosuvastatinandvadadustatacasereport AT harukisara rhabdomyolysiscausedbyinteractionbetweenrosuvastatinandvadadustatacasereport AT hatayusuke rhabdomyolysiscausedbyinteractionbetweenrosuvastatinandvadadustatacasereport AT hiragamadoka rhabdomyolysiscausedbyinteractionbetweenrosuvastatinandvadadustatacasereport AT yumotoshinya rhabdomyolysiscausedbyinteractionbetweenrosuvastatinandvadadustatacasereport AT kaiyutaka rhabdomyolysiscausedbyinteractionbetweenrosuvastatinandvadadustatacasereport |